Chief Physician of RCMG Sergey Voronin Took Part in the International Pharmaceutical Forum «Pharmacy-2022»
On November 24-26, 2022 at the Innovation Centre «Skolkovo», Amalthea HALL, the 29th International Pharmaceutical Forum-Exhibition «Pharmacy-2022» was held.
Forum-exhibition «Pharmacy» is the key annual event of the Russian pharmacy market, uniting the participants of the pharmaceutical industry - manufacturers and distributors of medicines, representatives of pharmacies and pharmacy networks, practitioners and developers of new medicines.
During three days, more than 3000 pharmacists, heads of pharmacies, managers of pharmacy networks, representatives of private and public medical institutions, pharmaceutical companies from 73 regions of the Russian Federation worked at the forum site, as well as from Armenia, Azerbaijan, Belarus, Kyrgyzstan, Tajikistan, Turkmenistan, UAE, Algeria, India, China, Thailand, Iran, Libya, Sri Lanka and Pakistan.
Sergey Voronin, PhD, chief physician of the Research Centre for Medical Genetics, took part in the strategic session «Pharmacy Production of Medications as a Key Vector of Development of Personalized Approach in Treatment of Patients» with a report on the interaction of the medical genetic service of Russia and pharmacies in the prevention and treatment of hereditary and (or) congenital pathology.
The moderator of the section was Airat Fattakhov, deputy of the State Duma of the Russian Federation.
The following issues were discussed:
- Development of pharmacy production of medications
- Establishment of a regulatory framework for the development of pharmacy production of medications
- Quality assurance and control of pharmacy preparations
- Interaction of healthcare regulators and organizers with the NPO.
Sergey Voronin touched upon the issue of pharmacy making medicines as one of the ways to solve the problems of medication supply for patients with orphan diseases.
“The forum raised questions about the need to personalize medical preparations, the need to provide patients with ultra-rare diseases, as well as the existing practice of providing patients with hereditary orphan diseases, for example, in the event of disruption of the urea cycle. Also discussed were the use of medications in the treatment of spinal muscular atrophy, the possibility of their manufacturing, as well as the need for changes in the potential importance of these medications and the number of patients, given the expansion of the neonatal screening programme from January 1, 2023”, - said Sergey Voronin.
For more information: https://www.aptekaexpo.ru